One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial

被引:61
作者
Kliewer, Kara L. [1 ]
Gonsalves, Nirmala [5 ]
Dellon, Evan S. [7 ]
Katzka, David A. [8 ]
Abonia, Juan P. [1 ]
Aceves, Seema S. [9 ]
Arva, Nicoleta C. [10 ]
Besse, John A. [1 ]
Bonis, PeterA [11 ]
Caldwell, Julie M. [1 ]
Capocelli, Kelley E. [13 ]
Chehade, Mirna [14 ]
Cianferoni, Antonella [16 ]
Collins, Margaret H. [3 ]
Falk, Gary W. [15 ]
Gupta, Sandeep K. [17 ]
Hirano, Ikuo [5 ]
Krischer, Jeffrey P. [18 ]
Leung, John [12 ]
Martin, Lisa J. [2 ]
Menard-Katcher, Paul [19 ]
Mukkada, Vincent A. [4 ]
Peterson, Kathryn A. [20 ]
Shoda, Tetsuo [1 ]
Spergel, Amanda K. Rudman [21 ]
Spergel, Jonathan M. [16 ]
Yang, Guang-Yu [6 ]
Zhang, Xue [2 ]
T Furuta, Glenn [22 ]
Rothenberg, Marc E. [1 ]
机构
[1] Univ Cincinnati, Div Allergy & Immunol, Coll Med, Cincinnati Childrens Hosp Med Ctr,Dept Pediat, Cincinnati, OH USA
[2] Univ Cincinnati, Div Human Genet, Coll Med, Cincinnati Childrens Hosp Med Ctr,Dept Pediat, Cincinnati, OH USA
[3] Univ Cincinnati, Div Pathol & Lab Med, Coll Med, Cincinnati Childrens Hosp Med Ctr,Dept Pediat, Cincinnati, OH USA
[4] Univ Cincinnati, Div Gastroenterol Hepatol & Nutr, Coll Med, Cincinnati Childrens Hosp Med Ctr,Dept Pediat, Cincinnati, OH USA
[5] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Cincinnati, OH USA
[6] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL USA
[7] Univ N Carolina, Div Gastroenterol & Hepatol, Sch Med, Chapel Hill, NC USA
[8] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[9] Univ Calif San Diego, Div Allergy & Immunol, Rady Childrens Hosp, San Diego, CA USA
[10] Northwestern Univ, Ann & Robert H Lurie Childrens Hosp, Dept Pathol & Lab, Feinberg Sch Med, Chicago, IL USA
[11] Tufts Med Ctr, Div Gastroenterol, Boston, MA USA
[12] Boston Specialists, Boston, MA USA
[13] Childrens Hosp Colorado, Dept Pathol, Aurora, CO USA
[14] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Eosinophil Disorders, New York, NY USA
[15] Univ Penn, Hosp, Div Gastroenterol, Sch Med, Philadelphia, PA USA
[16] Univ Penn, Childrens Hosp Philadelphia, Div Allergy & Immunol, Dept Pediat,Sch Med, Philadelphia, PA USA
[17] Indiana Univ Sch Med, Riley Hosp Children, Div Pediat Gastroenterol Hepatol & Nutr, Indianapolis, IN USA
[18] Univ S Florida, Hlth Informat Inst, Tampa, FL USA
[19] Univ Colorado Anschutz Med Campus, Div Gastroenterol Hepatol & Nutr, Aurora, CO USA
[20] Univ Utah, Div Gastroenterol, Salt Lake City, UT USA
[21] NIAID, NIH, Div Allergy Immunol & Transplantat, Bethesda, MD USA
[22] Univ Colorado, Digest Hlth Inst, Childrens Hosp Colorado, Gastrointestinal Eosinophil Dis Program,Sch Med, Aurora, CO USA
来源
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2023年 / 8卷 / 05期
关键词
EFFICACY; ADULTS; VALIDATION; REMISSION; CHILDREN;
D O I
10.1016/S2468-1253(23)00012-2
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Empirical elimination diets are effective for achieving histological remission in eosinophilic oesophagitis, but randomised trials comparing diet therapies are lacking. We aimed to compare a six-food elimination diet (6FED) with a one-food elimination diet (1FED) for the treatment of adults with eosinophilic oesophagitis. Methods We conducted a multicentre, randomised, open-label trial across ten sites of the Consortium of Eosinophilic Gastrointestinal Disease Researchers in the USA. Adults aged 18-60 years with active, symptomatic eosinophilic oesophagitis were centrally randomly allocated (1:1; block size of four) to 1FED (animal milk) or 6FED (animal milk, wheat, egg, soy, fish and shellfish, and peanut and tree nuts) for 6 weeks. Randomisation was stratified by age, enrolling site, and gender. The primary endpoint was the proportion of patients with histological remission (peak oesophageal count <15 eosinophils per high-power field [eos/hpf]). Key secondary endpoints were the proportions with complete histological remission (peak count <= 1 eos/hpf) and partial remission (peak counts <= 10 and <= 6 eos/hpf) and changes from baseline in peak eosinophil count and scores on the Eosinophilic Esophagitis Histology Scoring System (EoEHSS), Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), Eosinophilic Esophagitis Activity Index (EEsAI), and quality of life (Adult Eosinophilic Esophagitis Quality-of-Life and Patient Reported Outcome Measurement Information System Global Health questionnaires). Individuals without histological response to 1FED could proceed to 6FED, and those without histological response to 6FED could proceed to swallowed topical fluticasone propionate 880 mu g twice per day (with unrestricted diet), for 6 weeks. Histological remission after switching therapy was assessed as a secondary endpoint. Efficacy and safety analyses were done in the intention-to- treat (ITT) population. This trial is registered on ClinicalTrials.gov, NCT02778867, and is completed. Findings Between May 23, 2016, and March 6, 2019, 129 patients (70 [54%] men and 59 [46%] women; mean age 37 center dot 0 years [SD 10 center dot 3]) were enrolled, randomly assigned to 1FED (n=67) or 6FED (n=62), and included in the ITT population. At 6 weeks, 25 (40%) of 62 patients in the 6FED group had histological remission compared with 23 (34%) of 67 in the 1FED group (difference 6% [95% CI -11 to 23]; p=0 center dot 58). We found no significant difference between the groups at stricter thresholds for partial remission (=10 eos/hpf, difference 7% [-9 to 24], p=0 center dot 46; =6 eos/hpf, 14% [-0 to 29], p=0 center dot 069); the proportion with complete remission was significantly higher in the 6FED group than in the 1FED group (difference 13% [2 to 25]; p=0 center dot 031). Peak eosinophil counts decreased in both groups (geometric mean ratio 0 center dot 72 [0 center dot 43 to 1 center dot 20]; p=0 center dot 21). For 6FED versus 1FED, mean changes from baseline in EoEHSS (-0 center dot 23 vs -0 center dot 15; difference -0 center dot 08 [-0 center dot 21 to 0 center dot 05]; p=0 center dot 23), EREFS (-1 center dot 0 vs -0 center dot 6; difference -0 center dot 4 [-1 center dot 1 to 0 center dot 3]; p=0 center dot 28), and EEsAI (-8 center dot 2 vs -3 center dot 0; difference -5 center dot 2 [-11 center dot 2 to 0 center dot 8]; p=0 center dot 091) were not significantly different. Changes in quality-of-life scores were small and similar between the groups. No adverse event was observed in more than 5% of patients in either diet group. For patients without histological response to 1FED who proceeded to 6FED, nine (43%) of 21 reached histological remission; for patients without histological response to 6FED who proceeded to fluticasone propionate, nine (82%) of 11 reached histological remission. Interpretation Histological remission rates and improvements in histological and endoscopic features were similar after 1FED and 6FED in adults with eosinophilic oesophagitis. 6FED had efficacy in just less than half of 1FED nonresponders and steroids had efficacy in most 6FED non-responders. Our findings indicate that eliminating animal milk alone is an acceptable initial dietary therapy for eosinophilic oesophagitis. Copyright (c) 2023 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:408 / 421
页数:14
相关论文
共 36 条
  • [1] Efficacy of Dietary Interventions for Inducing Histologic Remission in Patients With Eosinophilic Esophagitis: A Systematic Review and Meta-analysis
    Arias, Angel
    Gonzalez-Cervera, Jesus
    Tenias, Jose M.
    Lucendo, Alfredo J.
    [J]. GASTROENTEROLOGY, 2014, 146 (07) : 1639 - 1648
  • [2] Functional role of kallikrein 5 and proteinase-activated receptor 2 in eosinophilic esophagitis
    Azouz, Nurit P.
    Klingler, Andrea M.
    Pathre, Purnima
    Besse, John A.
    Ben Baruch-Morgenstern, Netali
    Ballaban, Adina Y.
    Osswald, Garrett A.
    Brusilovsky, Michael
    Habel, Jeff E.
    Caldwell, Julie M.
    Ynga-Durand, Mario A.
    Abonia, Pablo J.
    Hu, Yueh-Chiang
    Wen, Ting
    Rothenberg, Marc E.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2020, 12 (545)
  • [3] Efficacy, Dose Reduction, and Resistance to High-Dose Fluticasone in Patients With Eosinophilic Esophagitis
    Butz, Bridget K.
    Wen, Ting
    Gleich, Gerald J.
    Furuta, Glenn T.
    Spergel, Jonathan
    King, Eileen
    Kramer, Robert E.
    Collins, Margaret H.
    Stucke, Emily
    Mangeot, Colleen
    Jackson, W. Daniel
    O'Gorman, Molly
    Abonia, J. Pablo
    Pentiuk, Scott
    Putnam, Philip E.
    Rothenberg, Marc E.
    [J]. GASTROENTEROLOGY, 2014, 147 (02) : 324 - +
  • [4] Eosinophilic Esophagitis in Adults Is Associated With IgG4 and Not Mediated by IgE
    Clayton, Frederic
    Fang, John C.
    Gleich, Gerald J.
    Lucendo, Alfredo J.
    Olalla, Jose M.
    Vinson, Laura A.
    Lowichik, Amy
    Chen, Xinjian
    Emerson, Lyska
    Cox, Kristen
    O'Gorman, Molly A.
    Peterson, Kathryn A.
    [J]. GASTROENTEROLOGY, 2014, 147 (03) : 602 - 609
  • [5] Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring
    Collins, M. H.
    Martin, L. J.
    Alexander, E. S.
    Boyd, J. Todd
    Sheridan, R.
    He, H.
    Pentiuk, S.
    Putnam, P. E.
    Abonia, J. P.
    Mukkada, V. A.
    Franciosi, J. P.
    Rothenberg, M. E.
    [J]. DISEASES OF THE ESOPHAGUS, 2017, 30 (03):
  • [6] Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders
    Dellon, Evan S.
    Simon, Dagmar
    Wechsler, Michael E.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2022, 10 (05) : 1169 - 1176
  • [7] Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
    Dellon, Evan S.
    Liacouras, Chris A.
    Molina-Infante, Javier
    Furuta, Glenn T.
    Spergel, Jonathan M.
    Zevit, Noam
    Spechler, Stuart J.
    Attwood, Stephen E.
    Straumann, Alex
    Aceves, Seema S.
    Alexander, Jeffrey A.
    Atkins, Dan
    Arva, Nicoleta C.
    Blanchard, Carine
    Bonis, Peter A.
    Book, Wendy M.
    Capocelli, Kelley E.
    Chehade, Mirna
    Cheng, Edaire
    Collins, Margaret H.
    Davis, Carla M.
    Dias, Jorge A.
    Di Lorenzo, Carlo
    Dohil, Ranjan
    Dupont, Christophe
    Falk, Gary W.
    Ferreira, Cristina T.
    Fox, Adam
    Gonsalves, Nirmala P.
    Gupta, Sandeep K.
    Katzka, David A.
    Kinoshita, Yoshikazu
    Menard-Katcher, Calies
    Kodroff, Ellyn
    Metz, David C.
    Miehlke, Stephan
    Muir, Amanda B.
    Mukkada, Vincent A.
    Murch, Simon
    Nurko, Samuel
    Ohtsuka, Yoshikazu
    Orel, Rok
    Papadopoulou, Alexandra
    Peterson, Kathryn A.
    Philpott, Hamish
    Putnam, Philip E.
    Richter, Joel E.
    Rosen, Rachel
    Rothenberg, Marc E.
    Schoepfer, Alain
    [J]. GASTROENTEROLOGY, 2018, 155 (04) : 1022 - +
  • [8] A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease
    Dellon, Evan S.
    Kim, Hannah P.
    Sperry, Sarah L. W.
    Rybnicek, David A.
    Woosley, John T.
    Shaheen, Nicholas J.
    [J]. GASTROINTESTINAL ENDOSCOPY, 2014, 79 (04) : 577 - +
  • [9] Elimination Diet Effectively Treats Eosinophilic Esophagitis in Adults; Food Reintroduction Identifies Causative Factors
    Gonsalves, Nirmala
    Yang, Guang-Yu
    Doerfler, Bethany
    Ritz, Sally
    Ditto, Anne M.
    Hirano, Ikuo
    [J]. GASTROENTEROLOGY, 2012, 142 (07) : 1451 - +
  • [10] Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items
    Hays, Ron D.
    Bjorner, Jakob B.
    Revicki, Dennis A.
    Spritzer, Karen L.
    Cella, David
    [J]. QUALITY OF LIFE RESEARCH, 2009, 18 (07) : 873 - 880